306 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp00008 | Citropin modified peptide-3 | GLFAVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Prostate tumor cell line | Prostate cancer | IC50 : 6 M |
| dbacp00017 | Citropin modified peptide-5 | GLFDVIKAVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Prostate tumor cell line | Prostate cancer | IC50 : 5 M |
| dbacp00026 | Citropin modified peptide-7 | GLFDVIKKVAAVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Prostate tumor cell line | Prostate cancer | IC50 : 5 M |
| dbacp00105 | Citropin modified peptide-11 | GLFDVIKKVASVIKGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Prostate tumor cell line | Prostate cancer | IC50 : 5 M |
| dbacp00114 | Citropin modified peptide-13 | GLFDVIKKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Prostate tumor cell line | Prostate cancer | IC50 : 5 M |
| dbacp00123 | Citropin modified peptide-14 | GLFDVIAKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Prostate tumor cell line | Prostate cancer | IC50 : 5 M |
| dbacp00157 | Citropin modified peptide-15 | GLFAVIKKVASVIKGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Prostate tumor cell line | Prostate cancer | IC50 : 5 M |
| dbacp00190 | Citropin modified peptide-16 | GLFAVIKKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Prostate tumor cell line | Prostate cancer | IC50 : 5 M |
| dbacp00224 | Citropin modified peptide-17 | GLFAVIKKVAAVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Prostate tumor cell line | Prostate cancer | IC50 : 5 M |
| dbacp00259 | Citropin modified peptide-18 | GLFAVIKKVAAVIRRL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Prostate tumor cell line | Prostate cancer | IC50 : 5 M |
| dbacp00268 | Citropin modified peptide-19 | GLFAVIKKVAKVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Prostate tumor cell line | Prostate cancer | IC50 : 5 M |
| dbacp00277 | Citropin modified peptide-22 | GLFKVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Prostate tumor cell line | Prostate cancer | IC50 : >10 µM |
| dbacp00299 | Citropin modified peptide-23 | GLFKVIKKVAKVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Prostate tumor cell line | Prostate cancer | IC50 : 5 M |
| dbacp00739 | 9R | RRRRRNWMWC | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | LNCaP | Prostate cancer | IC50 : 44 µM |
| dbacp00740 | 9R | RRRRRNWMWC | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | LNCaP | Prostate cancer | IC50 : 23 µM |
| dbacp00741 | 9R | RRRRRNWMWC | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | LNCaP | Prostate cancer | IC50 : 28 µM |
| dbacp00752 | 9S1R | RRRRRWCMNW | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | LNCaP | Prostate cancer | IC50 : 26 µM |
| dbacp00753 | 9S1R | RRRRRWCMNW | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | LNCaP | Prostate cancer | IC50 : 9 µM |
| dbacp00754 | 9S1R | RRRRRWCMNW | Not found | Cell membrane disintegration; Apoptosis | MTT/MTS assay | LNCaP | Prostate cancer | IC50 : 8 µM |
| dbacp00805 | A4K14-citropin1.1 | GLFAVIKKVASVIKGL | Synthetic construct | Cell membrane disintegration | CCK-8 test | C4-2B | Prostate cancer | IC50 : 29.05 μM |
| dbacp00807 | A4K14-citropin1.1 | GLFAVIKKVASVIKGL | Synthetic construct | Cell membrane disintegration | CCK-8 test | A549 | Prostate cancer | IC50 : 14.97 μM |
| dbacp00809 | A4K14-citropin1.1 | GLFAVIKKVASVIKGL | Synthetic construct | Cell membrane disintegration | CCK-8 test | U87 | Prostate cancer | IC50 : 14.8 μM |
| dbacp00811 | A4K14-citropin1.1 | GLFAVIKKVASVIKGL | Synthetic construct | Cell membrane disintegration | CCK-8 test | MCF-7 | Prostate cancer | IC50 : 14.16 μM |
| dbacp00817 | AaeAP1 | FLFSLIPSVIAGLVSAIRN | Aeneas fattailed scorpion | Not specified | MTT assay | H460 | Prostate cancer | Not found |
| dbacp00818 | AaeAP1 | FLFSLIPSVIAGLVSAIRN | Aeneas fattailed scorpion | Not specified | MTT assay | MB435s | Prostate cancer | Not found |
| dbacp00819 | AaeAP1 | FLFSLIPSVIAGLVSAIRN | Aeneas fattailed scorpion | Not specified | MTT assay | MCF-7 | Prostate cancer | Not found |
| dbacp00820 | AaeAP1 | FLFSLIPSVIAGLVSAIRN | Aeneas fattailed scorpion | Not specified | MTT assay | PC3 | Prostate cancer | Not found |
| dbacp00825 | AaeAP2 | FLFSLIPSAIAGLVSAIRN | Aeneas fattailed scorpion | Not specified | MTT assay | H460 | Prostate cancer | Not found |
| dbacp00826 | AaeAP2 | FLFSLIPSAIAGLVSAIRN | Aeneas fattailed scorpion | Not specified | MTT assay | MB435s | Prostate cancer | Not found |
| dbacp00827 | AaeAP2 | FLFSLIPSAIAGLVSAIRN | Aeneas fattailed scorpion | Not specified | MTT assay | MCF-7 | Prostate cancer | Not found |
| dbacp00828 | AaeAP2 | FLFSLIPSAIAGLVSAIRN | Aeneas fattailed scorpion | Not specified | MTT assay | PC3 | Prostate cancer | Not found |
| dbacp00833 | AAP-H | YVPGP | Marine invertebrates | Apoptosis inducing | MTT assay | DU-145 | Prostate cancer | IC50 : 9.605 mM |
| dbacp00834 | AAP-H | YVPGP | Marine invertebrates | Apoptosis inducing | MTT assay | DU-146 | Prostate cancer | IC50 : 7.910 mM |
| dbacp00835 | AAP-H | YVPGP | Marine invertebrates | Apoptosis inducing | MTT assay | DU-147 | Prostate cancer | IC50 : 2.298 mM |
| dbacp00979 | Adenoregulin | GLWSKIKEVGKEAAKAAAKAAGKAALGAVSEAV | South American frog, Giant leaf frog | Cell membrane disintegration | LDH leakage assay | PC-3 | Prostate cancer | GI50 : 1.24 ± 0.23 µM |
| dbacp00980 | Adenoregulin | GLWSKIKEVGKEAAKAAAKAAGKAALGAVSEAV | South American frog, Giant leaf frog | Cell membrane disintegration | LDH leakage assay | LNCaP | Prostate cancer | GI50 : 0.31 ± 0.15 µM |
| dbacp01157 | Anthopleura anjunae anti-tumor peptide | YVPGP | Sea anemone anti-tumor peptide | Apoptosis inducing | MTT Cell Proliferation and Cytotoxicity assay | DU-145 | Prostate cancer | IC50 : 9.605 μM |
| dbacp01165 | Antimicrobial peptide TsAP-1 | MQIKHLITLFFLVLIVADQCSAFLSLIPSLVGGSISAFKGRRKREISAQIEQYKDLQKREAELEELLDRLPMY | Brazilian scorpion | Antiproliferative action | Not specified | H838 | Prostate cancer | IC50 : 55.9 μM |
| dbacp01166 | Antimicrobial peptide TsAP- | MQIKHLITLFFLVLIVADQCSAFLSLIPSLVGGSISAFKGRRKREISAQIEQYKDLQKREAELEELLDRLPMY | Brazilian scorpion | Antiproliferative action | Not specified | H157 | Prostate cancer | IC50 : 52.5 μM |
| dbacp01168 | Antimicrobial peptide TsAP-2 | MQIKHLITIFFLVLIVADHCHAFLGMIPGLIGGLISAFKGRRKREITSQIEQYRNLQKREAELENLLANLPVY | Brazilian scorpion | Antiproliferative activity | Not specified | H157 | Prostate cancer | IC50 : 4.1 μM |
| dbacp01169 | Antimicrobial peptide TsAP-3 | MQIKHLITIFFLVLIVADHCHAFLGMIPGLIGGLISAFKGRRKREITSQIEQYRNLQKREAELENLLANLPVY | Brazilian scorpion | Antiproliferative activity | Not specified | H838 | Prostate cancer | IC50 : 11 μM |
| dbacp01170 | Antimicrobial peptide TsAP-4 | MQIKHLITIFFLVLIVADHCHAFLGMIPGLIGGLISAFKGRRKREITSQIEQYRNLQKREAELENLLANLPVY | Brazilian scorpion | Antiproliferative activity | Not specified | U251-MG | Prostate cancer | IC50 : 15.4 μM |
| dbacp01171 | Antimicrobial peptide TsAP-5 | MQIKHLITIFFLVLIVADHCHAFLGMIPGLIGGLISAFKGRRKREITSQIEQYRNLQKREAELENLLANLPVY | Brazilian scorpion | Antiproliferative activity | Not specified | PC3 | Prostate cancer | IC50 : 13.3 μM |
| dbacp01193 | ATAP-iRGD peptide-Parental | KFEPKSGWMTFLEVTGKIAEMLSLLKQYCRGDKGPDC | Anti apoptotic (MCL-1, BFL1) | Inducing apoptosis | MTT assay | DU-145 | Prostate cancer | IC50 : 1.6 μM |
| dbacp01194 | ATAP-iRGD-M1 | AFEPKSGWMTFLEVTGKIAEMLSLLKQYCRGDKGPDC | Anti apoptotic (MCL-1, BFL1) | Inducing apoptosis | MTT assay | DU-145 | Prostate cancer | IC50 : 36 μM |
| dbacp01195 | ATAP-iRGD-M2 | LFEPKSGWMTFLEVTGKIAEMLSLLKQYCRGDKGPDC | Anti apoptotic (MCL-1, BFL1) | Inducing apoptosis | MTT assay | DU-145 | Prostate cancer | IC50 : 68 μM |
| dbacp01196 | ATAP-iRGD-M3 | KFEPLSGWMTFLEVTGKIAEMLSLLKQYCRGDKGPDC | Anti apoptotic (MCL-1, BFL1) | Inducing apoptosis | MTT assay | DU-145 | Prostate cancer | IC50 : 25 μM |
| dbacp01197 | ATAP-iRGD-M5 | KFEPKSGWETFLEVTGKIAEMLSLLKQYCRGDKGPDC | Anti apoptotic (MCL-1, BFL1) | Inducing apoptosis | MTT assay | DU-145 | Prostate cancer | IC50 : 6 μM |
| dbacp01198 | ATAP-iRGD-M6 | KKFEPKSGWMTFLEVTGKIAEMLSLLKQYCRGDKGPDC | Anti apoptotic (MCL-1, BFL1) | Inducing apoptosis | MTT assay | DU-145 | Prostate cancer | IC50 : 3.1 μM |
| dbacp01199 | ATAP-iRGD-M7 | KFEPKSGWMTFLEVTGKIAEMLSLLKQYCRGDKGPDC | Anti apoptotic (MCL-1, BFL1) | Inducing apoptosis | MTT assay | DU-145 | Prostate cancer | IC50 : 2.1 μM |
| dbacp01200 | ATAP-iRGD-M8 | KKFEPKSGWMTFLEVTGKIAEMLSLLKQYCRGDKGPDC | Anti apoptotic (MCL-1, BFL1) | Inducing apoptosis | MTT assay | DU-145 | Prostate cancer | IC50 : 2.1 μM |
| dbacp01211 | ATP-binding cassette sub-family C member 2 | MLEKFCNSTFWNSSFLDSPEADLPLCFEQTVLVWIPLGYLWLLAPWQLLHVYKSRTKRSSTTKLYLAKQVFVGFLLILAAIELALVLTEDSGQATVPAVRYTNPSLYLGTWLLVLLIQYSRQWCVQKNSWFLSLFWILSILCGTFQFQTLIRTLLQGDNSNLAYSCLFFISYGFQILILIFSAFSENNESSNNPSSIASFLSSITYSWYDSIILKGYKRPLTLEDVWEVDEEMKTKTLVSKFETHMKRELQKARRALQRRQEKSSQQNSGARLPGLNKNQSQSQDALVLEDVEKKKKKSGTKKDVPKSWLMKALFKTFYMVLLKSFLLKLVNDIFTFVSPQLLKLLISFASDRDTYLWIGYLCAILLFTAALIQSFCLQCYFQLCFKLGVKVRTAIMASVYKKALTLSNLARKEYTVGETVNLMSVDAQKLMDVTNFMHMLWSSVLQIVLSIFFLWRELGPSVLAGVGVMVLVIPINAILSTKSKTIQVKnMKNKDKRLKIMNEILSGIKILKYFAWEPSFRDQVQNLRKKELKNLLAFSQLQCVVIFVFQLTPVLVSVVTFSVYVLVDSNNILDAQKAFTSITLFNILRFPLSMLPMMISSMLQASVSTERLEKYLGGDDLDTSAIRHDCNFDKAMQFSEASFTWEHDSEATVRDVNLDIMAGQLVAVIGPVGSGKSSLISAMLGEMENVHGHITIKGTTAYVPQQSWIQNGTIKDNILFGTEFNEKRYQQVLEACALLPDLEMLPGGDLAEIGEKGINLSGGQKQRISLARATYQNLDIYLLDDPLSAVDAHVGKHIFNKVLGPNGLLKGKTRLLVTHSMHFLPQVDEIVVLGNGTIVEKGSYSALLAKKGEFAKNLKTFLRHTGPEEEATVHDGSEEEDDDYGLISSVEEIPEDAASITMRRENSFRRTLSRSSRSNGRHLKSLRNSLKTRNVNSLKEDEELVKGQKLIKKEFIETGKVKFSIYLEYLQAIGLFSIFFIILAFVMNSVAFIGSNLWLSAWTSDSKIFNSTDYPASQRDMRVGVYGALGLAQGIFVFIAHFWSAFGFVHASNILHKQLLNNILRAPMRFFDTTPTGRIVNRFAGDISTVDDTLPQSLRSWITCFLGIISTLVMICMATPVFTIIVIPLGIIYVSVQMFYVSTSRQLRRLDSVTRSPIYSHFSETVSGLPVIRAFEHQQRFLKHNEVRIDTNQKCVFSWITSNRWLAIRLELVGNLTVFFSALMMVIYRDTLSGDTVGFVLSNALNITQTLNWLVRMTSEIETNIVAVERITEYTKVENEAPWVTDKRPPPDWPSKGKIQFNNYQVRYRPELDLVLRGITCDIGSMEKIGVVGRTGAGKSSLTNCLFRILEAAGGQIIIDGVDIASIGLHDLREKLTIIPQDPILFSGSLRMNLDPFNNYSDEEIWKALELAHLKSFVASLQLGLSHEVTEAGGNLSIGQRQLLCLGRALLRKSKILVLDEATAAVDLETDNLIQTTIQNEFAHCTVITIAHRLHTIMDSDKVMVLDNGKIIECGSPEELLQIPGPFYFMAKEAGIENVNSTKF | Human | Not specified | GFP assay | HEK293 | Prostate cancer | MIC : 2 μmol/L |
| dbacp01259 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Prostate tumor cell line | Prostate cancer | LC50 : 10 µM |
| dbacp01268 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Prostate tumor cell line | Prostate cancer | LC50 : 10 µM |
| dbacp01278 | Aurein 3.2 | GLFDIVKKIAGHIASSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Prostate tumor cell line | Prostate cancer | LC50 : 10 µM |
| dbacp01288 | Aurein 3.3 | GLFDIVKKIAGHIVSSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Prostate tumor cell line | Prostate cancer | LC50 : 10 µM |
| dbacp01299 | Aurein-1.3 | GLFDIIKKIAESF | Southern bell frog | Cell membrane disintegration | One-dose and five-dose assay | Not found | Prostate cancer | IC50 : 5 μM |
| dbacp01306 | Aurein-2.3 | MAFLKKSLFLVLFLGLVSLSICEKEKRQNGEDEDENEAANHEEGSEEKRGLFDIVKKVVGAIGSLGKRNDVE | Green and golden bell frog | Membrane disruption | Not specified | Human tumour cell lines | Prostate cancer | LC50 : 10-5 - 10-4 M |
| dbacp01318 | Aurein-2.5 | MAFLKKSLFLVLFLGLVSLSICEKEKRQNEEDEDENEAANHEEGSEEKRGLFDIVKKVVGAFGSLGKRNDLE | Green and golden bell frog | Not specified | Not specified | Not found | Prostate cancer | Not found |
| dbacp01327 | Aurein-2.5 | GLFDIVKKVVGAFGSL | Green and golden bell frog | Not specified | Not specified | Not found | Prostate cancer | Not found |
| dbacp01336 | Aurein-2.5 | GLFDIVKKVVGAFGSL | Green and golden bell frog | Cell membrane disintegration | One-dose and five-dose assay | Not found | Prostate cancer | IC50 : 5 μM |
| dbacp01341 | Aurein-2.5 | MAFLKKSLFLVLFLGLVSLSICEKEKRQNEEDEDENEAANHEEGSEEKRGLFDIVKKVVGAFGSLGKRNDLE | Green and golden bell frog | Membrane disruption | Not specified | Human tumour cell lines | Prostate cancer | LC50 : 10-5 - 10-4 M |
| dbacp01354 | Aurein-2.7 | GLFDIAKKVIGVIGSL | Southern bell frog | Cell membrane disintegration | One-dose and five-dose assay | DU-145 | Prostate cancer | IC50 : 5 μM |
| dbacp01365 | Aurein-3.1 [Cleaved into: Aurein-3.1.1; Aurein-3.1.2] | GLFDIVKKIAGHIAGSI | Southern bell frog | Cell membrane disintegration | One-dose and five-dose assay | Not found | Prostate cancer | IC50 : 5 μM |
| dbacp01378 | Aurein-3.2 | GLFDIVKKIAGHIASSI | Southern bell frog | Cell membrane disintegration | One-dose and five-dose assay | Not found | Prostate cancer | IC50 : 5 μM |
| dbacp01390 | Aurein-3.3 [Cleaved into: Aurein-3.3.1] | GLFDIVKKIAGHIVSSI | Southern bell frog | Cell membrane disintegration | One-dose and five-dose assay | PC-3 | Prostate cancer | IC50 : 5 μM |
| dbacp01413 | Aurein1.2 | GLFDIIKKIAESF | Southern bell frog | Cell membrane disruption | Not specified | Prostate tumor cell line | Prostate cancer | LC50 : 10 µM |
| dbacp01422 | Aurein2.5 | GLFDIVKKVVGAFGSL | Southern bell frog | Cell membrane disruption | Not specified | Prostate tumor cell line | Prostate cancer | LC50 : 10 µM |
| dbacp01431 | Aurein2.6 | GLFDIAKKVIGVIGSL | Southern bell frog | Cell membrane disruption | Not specified | Prostate tumor cell line | Prostate cancer | LC50 : 10 µM |
| dbacp01437 | B1AW-K | FLPLLAGLAANFLPKIICKIARKC | Wuyi torrent frog | Cell membrane penetration | MTT assay | PC-3 | Prostate cancer | IC50 : 33.46 μM |
| dbacp01451 | Bassianolide nonribosomal cyclodepsipeptide synthetase | MEPPNNANTGQLGPTLPNGTVDLPTDLSREITRHFGLEQDEIEEILPCTPFQRDVIECASDDKRRAVGHVVYEIPEDVDTERLAAAWKATVRYTPALRTCIFTSETGNAFQVVLRDYFIFARMYCPSAHLKSAIVKDEATAAVAGPRCNRYVLTGEPNSKRRVLVWTFSHSFVDSAFQGRILQQVLAAYKDGHGRVFSLQPTTDLTESENGDHLSTPASERTVVIERATQFWQEKLHGLDASVFPHLPSHKRVPAIDARADHYLPCPPFIQHEWSSTTVCRTALAILLARYTHSSEALFGVVTEQSHEEHPLLLDGPTSTVVPFRVLCALNQSVSKVMEAITTYDHDMRQFAHAGLCNISRIGDDASAACGFQTVLMVTDSRTAGDDEIHQVLEESEKFIPCTDRALLLSCQMTDEGVLLVARYDQSILEPLQMARFLRQLGFLINKLQSTDGSPCVGQLDVLAPEDRTEIEGWNSEPLQTQDCLIHSEVVRNAGDTPNKPAVCAWDGEWTYSELNNVSSRLASYISSLDLGQQLIVPIYLEKSKWVMAAILAVLKAGHAFTLIDPNDPPARTAQIIKQASASIALTSALHQSKMQAVVGRCITVDDDLVQTLTTFEGSQVASAAKPGDLAYVIFTSGSTGDPKGIMIEHRAFYSSVVKFGKALGIRSSTRALQFATHGFGAFLLEVLTTLIHGGCICVPSDHDRMHNIPGFIRQNQINWMMATPSYMTTMKPEDVPGLETLVLVGEQMSSSINDVWLSELQLLDGYGQSESSSICFVGKIDDSSRDPNNLGWAIGAHSWIINPDNPDQLVPIGAIGELLIESPGIARGYLFSQSTETPFLERAPAWYASKQPPYGVKFYRTGDLARYAPDGTVICLGRMDSQVKIRGQRVELDAIENLLRRQFPSDVTVVAEAVKRSDLPSSVVITGFLISSEYVVGAPSTEDTYILDQVVTQEINAKMRQILPAHSIPSFYICMKSLPRTATGKVDRRKLRSIGSSLLALQAQSTAPRSSQAPDASAGVTKLEEVWMDIFNLTPNSHNIGGNFFALGGDSITAIKMVnMARAAGIQLKVSDIFQNPTLASLQAAIGGSSMTVTSIPALALDGPVEQSYSQGRLWFLDQLEIGANWYTIPYAVRLRGPLDVDALNRALLALEKRHETLRTTFEDQDGVGVQIIHETLLDQLRIINADHADYVQLLKQEQTAPFNLASESGWRVSLIRLDDDDNILSIVMHHIISDGWSIDVLRRELGQLYAAALHGADLFGSALSPLPIQYRDFSVWQKQDAQVAEHERQLQYWQKQLADCSPAKLPTDFHRPALLSGKATTVPVTITSELYYRLQEFCSTFNTTSFVVLLATFRAAHYRLTGVDDAVIGTPIANRNRHELENLIGFFVNTQCMRITINEDEDTFESLVRQVRSTTTAAFEHEDVPFERVVSAMLPGSRDLSQNPLAQLVFAIHSHKDLGKFELEALESEPLQNEVYTRFDAEFHFFQAPDGLTGYINFATELFKVETIQNVVSVFLQILRHGLEHPQTLISVVPLTDGLAELRSMGLLEIKKVEYPRDSSVVDVFRTQVASYPDTLAVVDSSSRLTYAELDHQSDLLATWLRQQNLPTEALVVVLAPRSCETIITFLGILKANLAYLPLDIRSPITRMRDVLSTLPGRTIALLCSDEVAPDFQLPSIELVRIADALEEAAGMTSLNGHEHVPVPSPSPTSLAYVLYTSGSTGRPKGVMIEHRAIVRLARSDIIPDYRPACGDTMAHMFNTAFDGATYEIYTMLLNGGTLVCVDYMDTLSPKSLEAVFKKEQVNATIMAPALLKLYLADARDALKGLDVLISGGDRFDPQDAVDAQSLVRGSCYNGYGPTENGVFSTVYKVDKNDPFVNGVPLGRAVNNSGAYVVDRNQQLVGPGIIGELVVTGDGLARGYTERAFDQNRFTQLKVEGQSVRGYRTGDRVRYRVGEGLIEFFGRMDFQFKIRSNRIEAGEVEAAILSHPAVRNAAVILRVEEKLEPEIVGFVVAEHDDTAEQEEAGDQVEGWQAFFESTTYTELDTVSSSEIGKDFKGWTSMYDGNEIDKAEMQEWLDDTIHTLTDGQALGHVLEIGTGSGMVLFNLGSGLQSFVGLEPSKSAAAFVNNAIKSTPALAGKAQVFVGTATDTNKLDDLHPDLVIFNSVLQYFPTRDYLERVVDALVHLRSAKRIFFGDVRSYATNRHFLAARAIYTLGNHTTKDEVRKKMAEMEEREEEFLVEPAFFTTLVNRLPDVRHVEIIPKnMQATNELSAYRYAAVVHLRGSDELTRPVHPIKMDDWVDFQASHMHKDALREYLRLAENTKTVAISNIPYGKTIFERQVVESLDETSEDAPHASLDGAAWISAVRSDAKARSSLSVPDLVLLAKETGFRVEVSAARQWSQSGALDAVFHRYPAEPGVRTLFQFPTDNDVRMSAPLTNQPLQRLQKRRVAVQVREWLQDRIPSYMIPSHIVALDQMPLNTSGKVDRKELSRQAKAIKKVQKSAPPTAPAFPLSEVEVMLCEELTKTFEMDVNITDDFFQLGGHSLLATRLVARISHRLGARLTVKDVFDYPVFSELADIIRQQLASKNTLLPTASAGGGGQDKKESAGVAPTTDMEAMLCEEFANILGMDVGITDNFFDLGGHSLMATRLAARIGHRLNTTISVKDIFSHPVIFQLSAKLEVSQLESSSGGTDIKMPDYTAFQLIPAADAEKFMQDHIYPQINFSQDMVQDVYLATHLQQCFLRDVFGRPKPLVPFYVEFPPDSNPHTLATACTSLVDKYDIFRTIFVEAEGNLYQVVLKHLNLDIDVVETDANVHKTSSDLVDAIAKEPVRLGQPMIQVKVLKQTSSVRVLLWLSHALYDGLSWEHIVRDLHILSKERSLPPATQFSRYMQYVDHTRGPGCDFWRDVLQNAPITNLSDAGSGGRPTKAGDPRVWHAGKVISGPSQAIRSSITQATVFNAACAIVLSKETGTDNVVFGRIVSGRQGLPVRWQNIIGPCTNAVPVRAVVDAHGNHQQMLRDLQEQYLLSLPYETIGFDEIKRSCTDWPDSARNYGCCVTYQNFEYHPESEVDQQRVEMGILAKKAELIKEEPLYNVAIAGEVEPDGVHLQVTVVVDSQLFSQEGATHLMEQVCNTFQALNASL | White muscardine disease fungus | Cell apoptosis | Not specified | PC-3M | Prostate cancer | Not found |
| dbacp01453 | Bassianolide nonribosomal cyclodepsipeptide synthetase | MEPPNNANTGQLGPTLPNGTVDLPTDLSREITRHFGLEQDEIEEILPCTPFQRDVIECASDDKRRAVGHVVYEIPEDVDTERLAAAWKATVRYTPALRTCIFTSETGNAFQVVLRDYFIFARMYCPSAHLKSAIVKDEATAAVAGPRCNRYVLTGEPNSKRRVLVWTFSHSFVDSAFQGRILQQVLAAYKDGHGRVFSLQPTTDLTESENGDHLSTPASERTVVIERATQFWQEKLHGLDASVFPHLPSHKRVPAIDARADHYLPCPPFIQHEWSSTTVCRTALAILLARYTHSSEALFGVVTEQSHEEHPLLLDGPTSTVVPFRVLCALNQSVSKVMEAITTYDHDMRQFAHAGLCNISRIGDDASAACGFQTVLMVTDSRTAGDDEIHQVLEESEKFIPCTDRALLLSCQMTDEGVLLVARYDQSILEPLQMARFLRQLGFLINKLQSTDGSPCVGQLDVLAPEDRTEIEGWNSEPLQTQDCLIHSEVVRNAGDTPNKPAVCAWDGEWTYSELNNVSSRLASYISSLDLGQQLIVPIYLEKSKWVMAAILAVLKAGHAFTLIDPNDPPARTAQIIKQASASIALTSALHQSKMQAVVGRCITVDDDLVQTLTTFEGSQVASAAKPGDLAYVIFTSGSTGDPKGIMIEHRAFYSSVVKFGKALGIRSSTRALQFATHGFGAFLLEVLTTLIHGGCICVPSDHDRMHNIPGFIRQNQINWMMATPSYMTTMKPEDVPGLETLVLVGEQMSSSINDVWLSELQLLDGYGQSESSSICFVGKIDDSSRDPNNLGWAIGAHSWIINPDNPDQLVPIGAIGELLIESPGIARGYLFSQSTETPFLERAPAWYASKQPPYGVKFYRTGDLARYAPDGTVICLGRMDSQVKIRGQRVELDAIENLLRRQFPSDVTVVAEAVKRSDLPSSVVITGFLISSEYVVGAPSTEDTYILDQVVTQEINAKMRQILPAHSIPSFYICMKSLPRTATGKVDRRKLRSIGSSLLALQAQSTAPRSSQAPDASAGVTKLEEVWMDIFNLTPNSHNIGGNFFALGGDSITAIKMVnMARAAGIQLKVSDIFQNPTLASLQAAIGGSSMTVTSIPALALDGPVEQSYSQGRLWFLDQLEIGANWYTIPYAVRLRGPLDVDALNRALLALEKRHETLRTTFEDQDGVGVQIIHETLLDQLRIINADHADYVQLLKQEQTAPFNLASESGWRVSLIRLDDDDNILSIVMHHIISDGWSIDVLRRELGQLYAAALHGADLFGSALSPLPIQYRDFSVWQKQDAQVAEHERQLQYWQKQLADCSPAKLPTDFHRPALLSGKATTVPVTITSELYYRLQEFCSTFNTTSFVVLLATFRAAHYRLTGVDDAVIGTPIANRNRHELENLIGFFVNTQCMRITINEDEDTFESLVRQVRSTTTAAFEHEDVPFERVVSAMLPGSRDLSQNPLAQLVFAIHSHKDLGKFELEALESEPLQNEVYTRFDAEFHFFQAPDGLTGYINFATELFKVETIQNVVSVFLQILRHGLEHPQTLISVVPLTDGLAELRSMGLLEIKKVEYPRDSSVVDVFRTQVASYPDTLAVVDSSSRLTYAELDHQSDLLATWLRQQNLPTEALVVVLAPRSCETIITFLGILKANLAYLPLDIRSPITRMRDVLSTLPGRTIALLCSDEVAPDFQLPSIELVRIADALEEAAGMTSLNGHEHVPVPSPSPTSLAYVLYTSGSTGRPKGVMIEHRAIVRLARSDIIPDYRPACGDTMAHMFNTAFDGATYEIYTMLLNGGTLVCVDYMDTLSPKSLEAVFKKEQVNATIMAPALLKLYLADARDALKGLDVLISGGDRFDPQDAVDAQSLVRGSCYNGYGPTENGVFSTVYKVDKNDPFVNGVPLGRAVNNSGAYVVDRNQQLVGPGIIGELVVTGDGLARGYTERAFDQNRFTQLKVEGQSVRGYRTGDRVRYRVGEGLIEFFGRMDFQFKIRSNRIEAGEVEAAILSHPAVRNAAVILRVEEKLEPEIVGFVVAEHDDTAEQEEAGDQVEGWQAFFESTTYTELDTVSSSEIGKDFKGWTSMYDGNEIDKAEMQEWLDDTIHTLTDGQALGHVLEIGTGSGMVLFNLGSGLQSFVGLEPSKSAAAFVNNAIKSTPALAGKAQVFVGTATDTNKLDDLHPDLVIFNSVLQYFPTRDYLERVVDALVHLRSAKRIFFGDVRSYATNRHFLAARAIYTLGNHTTKDEVRKKMAEMEEREEEFLVEPAFFTTLVNRLPDVRHVEIIPKnMQATNELSAYRYAAVVHLRGSDELTRPVHPIKMDDWVDFQASHMHKDALREYLRLAENTKTVAISNIPYGKTIFERQVVESLDETSEDAPHASLDGAAWISAVRSDAKARSSLSVPDLVLLAKETGFRVEVSAARQWSQSGALDAVFHRYPAEPGVRTLFQFPTDNDVRMSAPLTNQPLQRLQKRRVAVQVREWLQDRIPSYMIPSHIVALDQMPLNTSGKVDRKELSRQAKAIKKVQKSAPPTAPAFPLSEVEVMLCEELTKTFEMDVNITDDFFQLGGHSLLATRLVARISHRLGARLTVKDVFDYPVFSELADIIRQQLASKNTLLPTASAGGGGQDKKESAGVAPTTDMEAMLCEEFANILGMDVGITDNFFDLGGHSLMATRLAARIGHRLNTTISVKDIFSHPVIFQLSAKLEVSQLESSSGGTDIKMPDYTAFQLIPAADAEKFMQDHIYPQINFSQDMVQDVYLATHLQQCFLRDVFGRPKPLVPFYVEFPPDSNPHTLATACTSLVDKYDIFRTIFVEAEGNLYQVVLKHLNLDIDVVETDANVHKTSSDLVDAIAKEPVRLGQPMIQVKVLKQTSSVRVLLWLSHALYDGLSWEHIVRDLHILSKERSLPPATQFSRYMQYVDHTRGPGCDFWRDVLQNAPITNLSDAGSGGRPTKAGDPRVWHAGKVISGPSQAIRSSITQATVFNAACAIVLSKETGTDNVVFGRIVSGRQGLPVRWQNIIGPCTNAVPVRAVVDAHGNHQQMLRDLQEQYLLSLPYETIGFDEIKRSCTDWPDSARNYGCCVTYQNFEYHPESEVDQQRVEMGILAKKAELIKEEPLYNVAIAGEVEPDGVHLQVTVVVDSQLFSQEGATHLMEQVCNTFQALNASL | White muscardine disease fungus | Cell apoptosis | Not specified | HUVEC-2 | Prostate cancer | Not found |
| dbacp01454 | Bassianolide nonribosomal cyclodepsipeptide synthetase (BSLS) | MEPPNNANTGQLGPTLPNGTVDLPTDLSREITRHFGLEQDEIEEILPCTPFQRDVIECASDDKRRAVGHVVYEIPEDVDTERLAAAWKATVRYTPALRTCIFTSETGNAFQVVLRDCFIFARMYCPSAHLKSAIVKDEATAAVAGPRCNRYVLTGEPNSKRRVLVWTFSHSFVDSAFQGRILQQVLAAYKDEHGRVFSLQPTTDLVESENGDCLSTPASERTVGIERATQFWQEKLHGLDASVFPHLPSHKRVPAIDARADHYLPCPPFIQHEWSSTTVCRTALAILLARYTHSSEALFGVVTEQSHEEHPLLLDGPTSTVVPFRVLCAPNQSVSEVMEAITTYDHDMRQFAHAGLCNISRIGDDASAACGFQTVLMVTDSRTASADEIHHVLEEPEKFIPCTDRALLLSCQMTDEGVLLVARYDQSILEPLQMARFLRQLGFLINKLQSTDGSPCVGQLDVLAPEDRTEIEGWNSEPLQTQDCLIHSEVVKNADDTPNKPAVCAWDGEWTYSELNNVSSRLASYISSLDLGQQLIVPIYLEKSKWVMAAILAVLKAGHAFTLIDPNDPPARTAQIIKQASASIALTSALHQSKMQTVVGRCITVDDDLFQTLTTFEGSQVASAAKPGDLAYVIFTSGSTGDPKGIMIEHRAFYSSVVKFGKALGIRSSTRALQFATHGFGAFLLEVLTTLIHGGCICIPSDHDRMHNIPGFIRQSQINWMMATPSYMTTMKPEDVPGLETLVLVGEQMSSSINDVWLSELQLLDGYGQSESSSICFVGKISDSSRDPNNLGRAIGSHSWIVNPDNPDQLVPIGAIGELLIESPGIARGYLFSQSTETPFLERAPAWYASKQPPYGVKFYRTGDLARYAPDGTVICLGRMDSQVKIRGQRVELDAIENLLRRQFPSDVTVVAEAVKRSDLPSSVVITGFLISSEYVVGAPSTEDTYILDQAVTQEINAKMRQILPAHSIPSFYICMKSLPRTATGKVDRRKLRSIGSSLLALQAQSTAPRSSQAPDASAGVTKLEEVWMDIFNLTPNSHNIGGNFFALGGDSITAIKMVnMARAAGIQLKVSDIFQNPTLASLQAAIGGSSMTVTSIPALALDGPVEQSYSQGRLWFLDQLEIGANWYTIPYAVRLRGPLDVDALNRALLALEKRHETLRTTFEDQDGVGVQIIHETLLDQLRIINADHADYVQLLKQEQTAPFNLASESGWRVSLIRLDDDDNILSIVMHHIISDGWSIDVLRRELGQLYAAALHGADLFGSALSPLPIQYRDFSVWQKQDAQVAEHERQLQYWQKQLADCSPAKLPTDFHRPALLSGKATTVPVTITSELYYRLQEFCSTFNTTSFVVLLATFRAAHYRLTGVDDAVIGTPIANRNRHELENLIGFFVNTQCMRITINEDEETFESLVRQVRSTTTAAFEHEDVPFERVVSAMLPGSRDLSQNPLAQLVFAIHSHKDLGKFELEALESEPLQNEVYTRFDAEFHFFQAPDGLTGYINFATELFKVETIQNVVSVFLQILRHGLEHPQTLISVVPLTDGLAELRSMGLLEIKKVEYPRDSSVVDVFATQVASYPDTLAVVDSSSRLTYAELDHQSDLLATWLRQQNLPTEALVVVLAPRSCETIITFLGILKANLAYLPLDIRSPITRMRDVLSTLPGRTIALLCSDEVAPDFQLPSIELVRIADALEEAAGMTSLNGHEHVPVPSPSPTSLAYVLYTSGSTGRPKGVMIEHRAIVRLARSDIIPDYRPACGDTMAHMFNTAFDGATYEIYTMLLNGGTLVCVDYMDTLSPKSLEAVFKKEQVNATIMAPALLKLYLADARDALKGLDVLISGGDRFDPQDAVDAQSLVRGSCYNGYGPTENGVFSTVYKVDKNDPFVNGVPLGRAVNNSGAYVVDRNQQLVGPGIIGELVVTGDGLARGYTERAFDQNRFIQLKIEGQSVRGYRTGDRVRYRVGEGLIEFFGRMDFQFKIRSNRIEAGEVEAAILSHPAVRNAAVILHVQEKLEPEIVGFVVAEHDDTAEQEEAGDQVEGWQAFFESTTYTELDTVSSSEIGKDFKGWTSMYDGNEIDKAEMQEWLDDTIHTLTDGQALGHVLEIGTGSGMVLFNLGSGLQSFVGLEPSKSAAAFVNNAIKSTPALAGKAHVFVGTATDTNKLDDLHPDLVIFNSVLQYFPTRDYLEQVVDALVHLRSAKRIFFGDVRSYATNRHFLAARAIYTLGNHTTKDEVRKKMAEMEEREEEFLVEPAFFTTLVNRLPDVRHVEIIPKnMQATNELSAYRYAAVVHLRGPDELTRPVHLIKMDDWVDFQASHMHKDALREYLRLAENTKTVAISNIPYGKTIFERQVVESLDDTSEDAPHASLDGAAWISAVRSDAKARSSLSVPDLVLLAKETGFRVEVSAARQWSQSGALDAVFHRYHPAEPDVRTLFQFPTDNDVRMSALLTNQPLQRLQKRRVAVQVREWLQDRIPSYMIPSHIVALDQMPLNTSGKVDRKELSRQAKAIKKVQKSAPPTAPAFPLSEVEVMLCEELTKTFEMDVNITDDFFQLGGHSLLATRLVARISHRLGARLTVKDVFDYPVFSELADIIRQQLASKNTLLPTASAGGGGQDKKESAGVAPTTDMEAMLCEEFANILGMDVGITDNFFDLGGHSLMATRLAARIGHRLNTTISVKDIFSHPVIFQLSAKLEVSQLESSSGGTDIKMPDYTAFQLIPAADAEKFMQDHIYPQINFSQDMVQDVYLATHLQQCFLRDVFGRPKPLVPFYVEFPPDSNPHTLATACTSLVDKYDIFRTIFVEAEGNLYQVVLKHLNLDIDVVETDANVHKTSSDLVDAIAKEPVRLGQPMIQVKVLKQTSSVRVLLWLSHALYDGLSWEHIVRDLHILSKERSLPPATQFSRYMQYVDHTRGPGCDFWRDVLQNAPITNLSDAGSGGRPTKAGDPRVWHAGKVISGPSQAIRSSITQATVFNAACAIVLSKETGTDNVVFGRIVSGRQGLPVRWQNIIGPCTNAVPVRAVVDAHGNHQQMLRDLQEQYLLSLPYETIGFDEIKRSCTDWPDSARNYGCCVTYQNFEYHPESEVDQQRVEMGILAKKAELIKEEPLYNVAIAGEVEPDGVHLQVTVVVDSQLFSQEGATHLMEQVCNTFQALNASL | White muscardine disease fungus | Cell apoptosis | Not specified | PC-3M | Prostate cancer | Not found |
| dbacp01456 | Bassianolide nonribosomal cyclodepsipeptide synthetase (BSLS) | MEPPNNANTGQLGPTLPNGTVDLPTDLSREITRHFGLEQDEIEEILPCTPFQRDVIECASDDKRRAVGHVVYEIPEDVDTERLAAAWKATVRYTPALRTCIFTSETGNAFQVVLRDCFIFARMYCPSAHLKSAIVKDEATAAVAGPRCNRYVLTGEPNSKRRVLVWTFSHSFVDSAFQGRILQQVLAAYKDEHGRVFSLQPTTDLVESENGDCLSTPASERTVGIERATQFWQEKLHGLDASVFPHLPSHKRVPAIDARADHYLPCPPFIQHEWSSTTVCRTALAILLARYTHSSEALFGVVTEQSHEEHPLLLDGPTSTVVPFRVLCAPNQSVSEVMEAITTYDHDMRQFAHAGLCNISRIGDDASAACGFQTVLMVTDSRTASADEIHHVLEEPEKFIPCTDRALLLSCQMTDEGVLLVARYDQSILEPLQMARFLRQLGFLINKLQSTDGSPCVGQLDVLAPEDRTEIEGWNSEPLQTQDCLIHSEVVKNADDTPNKPAVCAWDGEWTYSELNNVSSRLASYISSLDLGQQLIVPIYLEKSKWVMAAILAVLKAGHAFTLIDPNDPPARTAQIIKQASASIALTSALHQSKMQTVVGRCITVDDDLFQTLTTFEGSQVASAAKPGDLAYVIFTSGSTGDPKGIMIEHRAFYSSVVKFGKALGIRSSTRALQFATHGFGAFLLEVLTTLIHGGCICIPSDHDRMHNIPGFIRQSQINWMMATPSYMTTMKPEDVPGLETLVLVGEQMSSSINDVWLSELQLLDGYGQSESSSICFVGKISDSSRDPNNLGRAIGSHSWIVNPDNPDQLVPIGAIGELLIESPGIARGYLFSQSTETPFLERAPAWYASKQPPYGVKFYRTGDLARYAPDGTVICLGRMDSQVKIRGQRVELDAIENLLRRQFPSDVTVVAEAVKRSDLPSSVVITGFLISSEYVVGAPSTEDTYILDQAVTQEINAKMRQILPAHSIPSFYICMKSLPRTATGKVDRRKLRSIGSSLLALQAQSTAPRSSQAPDASAGVTKLEEVWMDIFNLTPNSHNIGGNFFALGGDSITAIKMVnMARAAGIQLKVSDIFQNPTLASLQAAIGGSSMTVTSIPALALDGPVEQSYSQGRLWFLDQLEIGANWYTIPYAVRLRGPLDVDALNRALLALEKRHETLRTTFEDQDGVGVQIIHETLLDQLRIINADHADYVQLLKQEQTAPFNLASESGWRVSLIRLDDDDNILSIVMHHIISDGWSIDVLRRELGQLYAAALHGADLFGSALSPLPIQYRDFSVWQKQDAQVAEHERQLQYWQKQLADCSPAKLPTDFHRPALLSGKATTVPVTITSELYYRLQEFCSTFNTTSFVVLLATFRAAHYRLTGVDDAVIGTPIANRNRHELENLIGFFVNTQCMRITINEDEETFESLVRQVRSTTTAAFEHEDVPFERVVSAMLPGSRDLSQNPLAQLVFAIHSHKDLGKFELEALESEPLQNEVYTRFDAEFHFFQAPDGLTGYINFATELFKVETIQNVVSVFLQILRHGLEHPQTLISVVPLTDGLAELRSMGLLEIKKVEYPRDSSVVDVFATQVASYPDTLAVVDSSSRLTYAELDHQSDLLATWLRQQNLPTEALVVVLAPRSCETIITFLGILKANLAYLPLDIRSPITRMRDVLSTLPGRTIALLCSDEVAPDFQLPSIELVRIADALEEAAGMTSLNGHEHVPVPSPSPTSLAYVLYTSGSTGRPKGVMIEHRAIVRLARSDIIPDYRPACGDTMAHMFNTAFDGATYEIYTMLLNGGTLVCVDYMDTLSPKSLEAVFKKEQVNATIMAPALLKLYLADARDALKGLDVLISGGDRFDPQDAVDAQSLVRGSCYNGYGPTENGVFSTVYKVDKNDPFVNGVPLGRAVNNSGAYVVDRNQQLVGPGIIGELVVTGDGLARGYTERAFDQNRFIQLKIEGQSVRGYRTGDRVRYRVGEGLIEFFGRMDFQFKIRSNRIEAGEVEAAILSHPAVRNAAVILHVQEKLEPEIVGFVVAEHDDTAEQEEAGDQVEGWQAFFESTTYTELDTVSSSEIGKDFKGWTSMYDGNEIDKAEMQEWLDDTIHTLTDGQALGHVLEIGTGSGMVLFNLGSGLQSFVGLEPSKSAAAFVNNAIKSTPALAGKAHVFVGTATDTNKLDDLHPDLVIFNSVLQYFPTRDYLEQVVDALVHLRSAKRIFFGDVRSYATNRHFLAARAIYTLGNHTTKDEVRKKMAEMEEREEEFLVEPAFFTTLVNRLPDVRHVEIIPKnMQATNELSAYRYAAVVHLRGPDELTRPVHLIKMDDWVDFQASHMHKDALREYLRLAENTKTVAISNIPYGKTIFERQVVESLDDTSEDAPHASLDGAAWISAVRSDAKARSSLSVPDLVLLAKETGFRVEVSAARQWSQSGALDAVFHRYHPAEPDVRTLFQFPTDNDVRMSALLTNQPLQRLQKRRVAVQVREWLQDRIPSYMIPSHIVALDQMPLNTSGKVDRKELSRQAKAIKKVQKSAPPTAPAFPLSEVEVMLCEELTKTFEMDVNITDDFFQLGGHSLLATRLVARISHRLGARLTVKDVFDYPVFSELADIIRQQLASKNTLLPTASAGGGGQDKKESAGVAPTTDMEAMLCEEFANILGMDVGITDNFFDLGGHSLMATRLAARIGHRLNTTISVKDIFSHPVIFQLSAKLEVSQLESSSGGTDIKMPDYTAFQLIPAADAEKFMQDHIYPQINFSQDMVQDVYLATHLQQCFLRDVFGRPKPLVPFYVEFPPDSNPHTLATACTSLVDKYDIFRTIFVEAEGNLYQVVLKHLNLDIDVVETDANVHKTSSDLVDAIAKEPVRLGQPMIQVKVLKQTSSVRVLLWLSHALYDGLSWEHIVRDLHILSKERSLPPATQFSRYMQYVDHTRGPGCDFWRDVLQNAPITNLSDAGSGGRPTKAGDPRVWHAGKVISGPSQAIRSSITQATVFNAACAIVLSKETGTDNVVFGRIVSGRQGLPVRWQNIIGPCTNAVPVRAVVDAHGNHQQMLRDLQEQYLLSLPYETIGFDEIKRSCTDWPDSARNYGCCVTYQNFEYHPESEVDQQRVEMGILAKKAELIKEEPLYNVAIAGEVEPDGVHLQVTVVVDSQLFSQEGATHLMEQVCNTFQALNASL | White muscardine disease fungus | Cell apoptosis | Not specified | HUVEC-2 | Prostate cancer | Not found |
| dbacp01530 | BC46 | c[(bA)(bA)RKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Prostate cancer | Not found |
| dbacp01535 | BC48 | c[(bA)GRKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Prostate cancer | Not found |
| dbacp01540 | BC49 | c[(bA)(4aba)RKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Prostate cancer | Not found |
| dbacp01545 | BC50 | c[(4aba)(bA)RKD] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Prostate cancer | Not found |
| dbacp01550 | BC70 | c[(bA)(k)RKD(1-D-NAl)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Prostate cancer | Not found |
| dbacp01555 | BC71 | c[(bA)(k)RKD(2-D-NAl)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Prostate cancer | Not found |
| dbacp01560 | BC72 | c[(bA)(o)RKD(f)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Prostate cancer | Not found |
| dbacp01565 | BC74 | c[(bA)(k)(Fguan)KD(f)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Prostate cancer | Not found |
| dbacp01570 | BC75 | c[(bA)(k)RKD(D-Bip)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Prostate cancer | Not found |
| dbacp01575 | BC81 | c[(2233tmpa)(k)RKD(2-D-NAl)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Prostate cancer | Not found |
| dbacp01580 | BC83 | c[(bA)(k)RKD(D-2Anth)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Prostate cancer | Not found |
| dbacp01585 | BC84 | c[(bA)(k)RKD(w)] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Prostate cancer | Not found |
| dbacp01628 | BIM BH3 (E158S) | EIWIAQELRRIGDSFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | MTT assay | Not found | Prostate cancer | Not found |
| dbacp01629 | BIM BH3 (I155R, E158A) | EIWIAQELRRRGDAFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | MTT assay | Not found | Prostate cancer | Not found |
| dbacp01630 | BIM BH3 (I155R, E158S) | EIWIAQELRRRGDSFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | MTT assay | Not found | Prostate cancer | Not found |
| dbacp01631 | BIM BH3 (R154S, I155R, E158S) | EIWIAQELRSRGDSFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | MTT assay | Not found | Prostate cancer | Not found |
| dbacp01815 | BIM XXA1 | RPEIWYAQGLKRFGDEFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | MTT assay | Not found | Prostate cancer | Not found |
| dbacp01923 | Brevinin-1-AW | FLPLLAGLAANFLPQIICKIARKC | Skin secretion, the Wuyi torrent frog, China, Asia | Cell membrane penetration | MTT assay | PC-3 | Prostate cancer | IC50 : 33.46 μM |
| dbacp01942 | Brevinin-1H | FALGAVTKVLPKLFCLITRKC | Hainan Torrent Frog | Membrane disruption | MTT assay | PC-3 | Prostate cancer | IC50 : 3.37 to 5.87 µM |
| dbacp02045 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 12 µg/ml |
| dbacp02046 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | DU-145 | Prostate cancer | IC50 : 15.3 µg/ml |
| dbacp02495 | Citropin 1.1 | GLFDVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Prostate tumor cell line | Prostate cancer | IC50 : 5 M |
| dbacp02506 | Citropin 1.1D | glfdvikkvasviggl | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Prostate tumor cell line | Prostate cancer | IC50 : 5 M |
| dbacp02620 | D-K6L9 | LKlLKKLlkKLLkLL | Not found | Necrosis; Membrane disruption | Enzyme Immunoassay (EIA) | 22RV1 | Prostate cancer | LC50 : 6 µMol/L |
| dbacp02622 | D-K6L9 | LKlLKKLlkKLLkLL | Not found | Necrosis; Membrane disruption | Enzyme Immunoassay (EIA) | MB-231 | Prostate cancer | LC50 : 3 µMol/L |
| dbacp02631 | DC1 | GAFLKCGESCVYLPCLTTVVGCSCQNSVCYRD | Snake-needle grass | Apoptosis inducing | Colorimetric Cell viability assay,Migration assay ,Wound healing assay and Human prostate cancer xenograft assay | DC3 | Prostate cancer | Not found |
| dbacp02632 | DC1 | GAFLKCGESCVYLPCLTTVVGCSCQNSVCYRD | Snake-needle grass | Apoptosis inducing | Colorimetric Cell viability assay,Migration assay ,Wound healing assay and Human prostate cancer xenograft assay | LNCap | Prostate cancer | Not found |
| dbacp02633 | DC2 | GAVPCGETCVYLPCITPDIGCSCQNKVCYRD | Snake-needle grass | Apoptosis inducing | Colorimetric Cell viability assay,Migration assay ,Wound healing assay and Human prostate cancer xenograft assay | DC3 | Prostate cancer | Not found |
| dbacp02634 | DC2 | GAVPCGETCVYLPCITPDIGCSCQNKVCYRD | Snake-needle grass | Apoptosis inducing | Colorimetric Cell viability assay,Migration assay ,Wound healing assay and Human prostate cancer xenograft assay | LNCap | Prostate cancer | Not found |
| dbacp02635 | DC3 | GTSCGETCVLLPCLSSVLGCTCQNKRCYKD | Snake-needle grass | Apoptosis inducing | Colorimetric Cell viability assay,Migration assay ,Wound healing assay and Human prostate cancer xenograft assay | DC3 | Prostate cancer | Not found |
| dbacp02636 | DC3 | GTSCGETCVLLPCLSSVLGCTCQNKRCYKD | Snake-needle grass | Apoptosis inducing | Colorimetric Cell viability assay,Migration assay ,Wound healing assay and Human prostate cancer xenograft assay | LNCap | Prostate cancer | Not found |
| dbacp02653 | Dermaseptin PS4 | MDILKKSIFLVLFLGLVSLSICEEEKRENEDEEKQEDDEQSEEKRALWKTLLKHVGKAAGKAALNAVTDMVNQGEQ | Sauvage's leaf frog | Membrane disruption | Lactate dehydrogenase (LDH) cytotoxicity assay, MTT assay | PC-3 | Prostate cancer | MIC : 10−9 to 10−4 M |
| dbacp02685 | Dermaseptin-PH | ALWKEVLKNAGKAALNEINNLV | Orange-legged leaf frog, Northern orange-legged leaf frog, South America | Cell membrane permeabilization | MTT cell proliferation assay | U251MG | Prostate cancer | IC50 : 2.36 μM |
| dbacp02697 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | MCF-7 | Prostate cancer | IC50 : 7.44 μM |
| dbacp02702 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | U251MG | Prostate cancer | IC50 : 49.51 μM |
| dbacp02707 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | H157 | Prostate cancer | IC50 : 25.51 μM |
| dbacp02712 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Prostate cancer | IC50 : 21.78 μM |
| dbacp02717 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Prostate cancer | IC50 : 28.95 μM |
| dbacp02722 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | HMEC-1 | Prostate cancer | IC50 : 51.04 μM |
| dbacp02729 | Dermaseptin-PS4 | ALWKTLLKHVGKAAGKAALNAVTDMVNQ | Waxy monkey tree frog | Membrane disruption | Lactate dehydrogenase (LDH) cytotoxicity assay, MTT assay | PC-3 | Prostate cancer | MIC : 10−9 to 10−4 M |
| dbacp02744 | Dex-(KW)3 | KWKWKW | Synthetic | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | At 10 µM 60% viablity |
| dbacp02758 | Dimer of peptide-paclitaxel conjugate | (K-Aib-C(CH2CO-2'-Pac))2 | Synthetic peptide paclitaxel conjugate | Not specified | MTT/MTS assay | DU | Prostate cancer | IC50 : 2.85 nM |
| dbacp02785 | dLL-37(17-32)c | FKRIVQRIKDFLRNLV | LL-37, a series of peptide fragments | Cell membrane disintegration | MTT/MTS assay | HBMEC | Prostate cancer | Not found |
| dbacp02801 | Dolastatin 10 | 2-[[2-(dimethylamino)-3-methylbutanoyl]amino]-N-[3-methoxy-1-[2-[1-methoxy-2-methyl-3-oxo-3-[[2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N,3-dimethylbutaNAmide | Wedge sea hare | Apoptosis inducing | TUNEL assay | DU-145 | Prostate cancer | IC50 : 0.5 nM |
| dbacp02828 | EGFR-related peptide | ERRP | EGFR-related peptide | Apoptosis | MTT/MTS assay | PC-3 | Prostate cancer | 30% Cell viability at 5 µg/ml |
| dbacp02976 | GA-K3 | FLGWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 47.69 µM |
| dbacp02983 | GA-K3 | FLGWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 47.69 µM |
| dbacp02990 | GA-K4 | FLKWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 :29.10 µM |
| dbacp02997 | GA-K4 | FLKWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 29.10 µM |
| dbacp03004 | GA-W3 | FLGWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 46.51 µM |
| dbacp03011 | GA-W3 | FLGWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 46.51 µM |
| dbacp03018 | GA-W4 | FLWWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 24.32 µM |
| dbacp03025 | GA-W4 | FLWWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 24.32 µM |
| dbacp03030 | Gageostatin A | ELLVDLL | Bacillus subtilis | Perturbation of the cell membrane | Sulforhodamine B (SBR) assay | PC-3 | Prostate cancer | GI50 : 4.6–19.6 μg/mL |
| dbacp03156 | GR01 | c[CRKDC]Disulfidebridge | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Prostate cancer | Not found |
| dbacp03161 | GR16 | c[KRKDF] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Prostate cancer | Not found |
| dbacp03166 | GR35 | c[KRAAF] | AMOP domain of ISM trigger apoptosis | Inducing apoptosis | LDH assay | HUVECs | Prostate cancer | Not found |
| dbacp03284 | Hc-CATH | KFFKRLLKSVRRAVKKFRKKPRLIGLSTLL | Green paddy frog | Not specified | MTT assay | HepG2 | Prostate cancer | 4.70% cell death at 200 µg/ml |
| dbacp03286 | Hc-CATH | KFFKRLLKSVRRAVKKFRKKPRLIGLSTLL | Green paddy frog | Not specified | MTT assay | PC-3 | Prostate cancer | 3.63% cell death at 200 µg/ml |
| dbacp03288 | Hc-CATH | KFFKRLLKSVRRAVKKFRKKPRLIGLSTLL | Green paddy frog | Not specified | MTT assay | L929 | Prostate cancer | 1.30% cell death at 200 µg/ml |
| dbacp03291 | HECI | TVLRGCWTFSFPPKPCI | Hylarana erythraea | Cell membrane disintegration | MTT anti-proliferation assay | PC-3 | Prostate cancer | MIC : 1µM |
| dbacp03341 | Human placenta hydrolysate (HPH) | NA | Human | Not specified | Not specified | PC-3 | Prostate cancer | IC50 : 1.3-2.8 mg/ml |
| dbacp03397 | Interferon gamma (IFN-gamma) | MKYTSYILAFQLCIVLGSLGCYCQDPYVKEAENLKKYFNAGHSDVADNGTLFLGILKNWKEESDRKIMQSQIVSFYFKLFKNFKDDQSIQKSVETIKEDMNVKFFNSNKKKRDDFEKLTNYSVTDLNVQRKAIHELIQVMAELSPAVKTGKRKRSQMLFRGRRASQ | Chimpanzee | Apoptosis; Immunomodulatory activity | Not specified | Not found | Prostate cancer | Not found |
| dbacp03489 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | MCF-7 | Prostate cancer | IC50 : 8.64μM |
| dbacp03494 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | U251MG | Prostate cancer | IC50 : 18.51μM |
| dbacp03499 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | H157 | Prostate cancer | IC50 : 9.88μM |
| dbacp03504 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Prostate cancer | IC50 : 9.97μM |
| dbacp03509 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PANC-1 | Prostate cancer | IC50 : 11.17μM |
| dbacp03514 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | HMEC-1 | Prostate cancer | IC50 : 48.80μM |
| dbacp03754 | LHRH–BH3 peptide luteinizing hormone-releasing hormone (LHRH) | QHWSYGLRPGMGQVGRQLAIIGDDINRRY | Effectors (BAK, BAX) | Inducing apoptosis | Cytotoxicity assay, MTT assay | PC-3 | Prostate cancer | Not found |
| dbacp04149 | LL 37 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | Also known human cathelicidin | Plasma membrane perturbations | MTT/MTS assay | LNCaP | Prostate cancer | LC50 : 27 at 100 µM |
| dbacp04157 | LL-37(1-12) | LLGDFFRKSKEK | LL-37,a series of peptide fragments | Cell membrane disintegration | MTT/MTS assay | HBMEC | Prostate cancer | Not found |
| dbacp04160 | LL-37(1-4,17-27) | LLGDFKRIVQRIKDF | LL-37,a series of peptide fragments | Cell membrane disintegration | MTT/MTS assay | HBMEC | Prostate cancer | Not found |
| dbacp04163 | LL-37(13-37) | IGKEFKRIVQRIKDFLRNLVPRTES | LL-37,a series of peptide fragments | Cell membrane disintegration | MTT/MTS assay | HBMEC | Prostate cancer | LC50 : 38 µM |
| dbacp04166 | LL-37(13-37)(C-terminal fragment of LL-37; Human, mammals, animals) | IGKEFKRIVQRIKDFLRNLVPRTES | Human | Not specified | MTT assay | HBMEC | Prostate cancer | LC50 : 38 ± 3 μM |
| dbacp04169 | LL-37(17-29) | FKRIVQRIKDFLR | LL-37,a series of peptide fragments | Cell membrane disintegration | MTT/MTS assay | HBMEC | Prostate cancer | LC50 : 55 µM |
| dbacp04173 | LL-37(17-29)(C-terminal fragment of LL-37; Human, mammals, animals) | FKRIVQRIKDFLRNLV | Human | Not specified | MTT assay | HBMEC | Prostate cancer | LC50 : 55 ± 2 μM |
| dbacp04176 | LL-37(17-32)(C-terminal fragment of LL-37; Human, mammals, animals) | FKRIVQRIKDFLRNLV | Human | Not specified | MTT assay | HBMEC | Prostate cancer | LC50 : 25 ± 1 μM |
| dbacp04179 | LL-37(17-32)b | FKRIVQRIKDFLRNLV | LL-37,a series of peptide fragments | Cell membrane disintegration | MTT/MTS assay | HBMEC | Prostate cancer | LC50 : 25 µM |
| dbacp04295 | ltc2aG11A | GLFGKLIKKFARKAISYAVKKARGKH | Central Asian spider | Membrane disruption | LDH leakage assay | Prostate tumor cell line | Prostate cancer | Not found |
| dbacp04341 | Lycosin-1 | Ac-KGWFKAMKSIAKFIAKEKLKEHL-amide | Tarantula wolf spider | Inhibit the migration of prostate cancer cell; Induce apoptosis | MTT assay | DU-145 | Prostate cancer | MIC : 10 μM |
| dbacp04342 | Lycosin-1 | Ac-KGWFKAMKSIAKFIAKEKLKEHL-amide | Tarantula wolf spider | Inhibit the migration of prostate cancer cell; Induce apoptosis | MTT assay | PC-3 | Prostate cancer | MIC : 20 μM |
| dbacp04364 | Lytic | KLlLKlLkkLLKlLKKK | Transferrin receptor (TfR) | Disintegration of cell membrane | WST-1 assay | LNCaP | Prostate cancer | IC50 : 15.8 µM |
| dbacp04451 | Maculatin 1.3 | GLLGLLGSVVSHVVPAIVGHF | Fringed Tree Frog, Australia | Disruption of cancer membrane integrity | Not specified | Not specified | Prostate cancer | MIC : 1 – 100 µg/ml |
| dbacp04462 | Maculatin 1.4 | GLLGLLGSVVSHVLPAITQHL | Fringed Tree Frog, Australia | Disruption of cancer cell membrane integrity | Not specified | Not specified | Prostate cancer | MIC : 1 – 100 µg/ml |
| dbacp04470 | Maculatin 1.4 | GLLGLLGSVVSHVLPAITQHL | Fringed Tree Frog, Australia | Disruption of cancer cell membrane integrity | Not specified | Not specified | Prostate cancer | IC50 : 10−5 - 10−6 M |
| dbacp04496 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | PC-3 | Prostate cancer | IC50 : >200 µg/ml |
| dbacp04514 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | PC-3 | Prostate cancer | IC50 : 53 µg/ml |
| dbacp04524 | Magainin B | GIGKFLHAAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | PC-3 | Prostate cancer | IC50 : 41 µg/ml |
| dbacp04540 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | PC-3 | Prostate cancer | IC50 : 47 µg/ml |
| dbacp04595 | Mauriporin | MNKKTLLVIFFITMLIVDEVNSFKIGGFIKKLWRSKLAKKLRAKGRELLKDYANRVINGGPEEEAAVPAERRR | Fat-tailed scorpion | Induce cell apoptosis; Targets on the cell membranes and caused membrane lysis | MTT assay, Lactate dehydrogenase (LDH) Release assay | PC-3 | Human Prostate cancer | IC50 : 27.9 μM - 283.3 μM |
| dbacp04596 | Mauriporin (Non-disulfide-bridged peptide 2.8) (NDBP-2.8) | MNKKTLLVIFFITMLIVDEVNSFKIGGFIKKLWRSKLAKKLRAKGRELLKDYANRVINGGPEEEAAVPAERRR | Fat-tailed scorpion | Anti-proliferative action | Not specified | PC3 | Prostate cancer | IC50 : 7.7 μM |
| dbacp04597 | Mauriporin (Non-disulfide-bridged peptide 2.8) (NDBP-2.8) | MNKKTLLVIFFITMLIVDEVNSFKIGGFIKKLWRSKLAKKLRAKGRELLKDYANRVINGGPEEEAAVPAERRR | Fat-tailed scorpion | Anti-proliferative action | Not specified | LnCAP | Prostate cancer | IC50 : 7.8 μM |
| dbacp04598 | Mauriporin (Non-disulfide-bridged peptide 2.8) (NDBP-2.8) | MNKKTLLVIFFITMLIVDEVNSFKIGGFIKKLWRSKLAKKLRAKGRELLKDYANRVINGGPEEEAAVPAERRR | Fat-tailed scorpion | Anti-proliferative action | Not specified | DU-145 | Prostate cancer | IC50 : 4.4 μM |
| dbacp05029 | p-BIM BH3 (I155R, E158S) | EIWIAQELRRRGDpSFNAYYAR‘pS’standsforthephosphorylatedserine | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | MTT assay | Not found | Prostate cancer | Not found |
| dbacp05030 | p-BIM BH3 (R154S, I155R, E158S) | EIWIAQELRSRGDpSFNAYYAR‘pS’standsforthephosphorylatedserine | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | MTT assay | Not found | Prostate cancer | Not found |
| dbacp05071 | P3Bax | MDGSGEQLGSGGPTSSEQIMKTGAFLLQGFIQ | Effectors (BAK, BAX) | Inducing apoptosis | Cell survival assay | NRP-154 | Prostate cancer | Not found |
| dbacp05244 | Pentapeptide (ILYMP) | ILYMP | Marine invertebrates | Inducing apoptosis | MTT assay | DU-145 | Prostate cancer | IC50 :11.25 mM |
| dbacp05245 | pep1 | FKCRRWQWRMKKLGAPSITCVR | Bovine lactoferrin (Lf-B) | Activating an apoptosis-inducing pathway | MTT/MTS assay | HL-60 | Prostate cancer | IC50 :77 µM |
| dbacp05485 | Pexiganan | GIGKFLKKAKKFGKAFVKILKK | Analog of African clawed frog | Plasma membrane perturbations | MTT/MTS assay | LNCaP | Prostate cancer | LC50 : 6 at 100 µM |
| dbacp05525 | Phylloseptin-PBa1 | FLSLIPHIASGIASLVKNF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | U145 | Prostate cancer | IC50 : approx. 0.29 µM |
| dbacp05526 | Phylloseptin-PBa1 | FLSLIPHIASGIASLVKNF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | PC3 | Prostate cancer | IC50 : approx. 0.29 µM |
| dbacp05527 | Phylloseptin-PBa1 | FLSLIPHIASGIASLVKNF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | LNCaP | Prostate cancer | IC50 : approx. 0.29 µM |
| dbacp05536 | Phylloseptin-PBa2 | FLSLLPHIASGIASLVSKF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | U145 | Prostate cancer | IC50 : approx. 0.50 µM |
| dbacp05537 | Phylloseptin-PBa2 | FLSLLPHIASGIASLVSKF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | PC3 | Prostate cancer | IC50 : approx. 0.50 µM |
| dbacp05538 | Phylloseptin-PBa2 | FLSLLPHIASGIASLVSKF | Burmeister's leaf frog, Brazil, South America | Disruption of cell membranes | MTT cell viability assay | LNCaP | Prostate cancer | IC50 : approx. 0.50 µM |
| dbacp05720 | PTP4 | FLKLLKKLAAKFLPTIICKISYKC | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 18.63 µg/ml |
| dbacp05725 | PTP5 | FLKLLKKLAAKLF | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | PC-3 | Prostate cancer | Not found |
| dbacp05730 | PTP6 | FLKLLKKLAAKLF | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 13.27 µg/ml |
| dbacp05735 | PTP7 | FLGALFKALSKLL | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 5.01 µg/ml |
| dbacp05740 | PTP8 | FLKLLAGLLKNFA | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 28.9 µg/ml |
| dbacp05794 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | H157 | Prostate cancer | IC50 : 843.40 µM |
| dbacp05797 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | H157 | Prostate cancer | IC50 : 843.40 µM |
| dbacp05801 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | MBD-MB-435s | Prostate cancer | IC50 : 872.70 µM |
| dbacp05805 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | PC-3 | Prostate cancer | IC50 : 283.90 µM |
| dbacp05809 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | U251-MG | Prostate cancer | IC50 : 104.10 µM |
| dbacp05813 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | MCF-7 | Prostate cancer | IC50 : 109.30 µM |
| dbacp05817 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | HMEC-1 | Prostate cancer | IC50 : 588.20 µM |
| dbacp05878 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | H157 | Prostate cancer | IC50 : 5.90 µM |
| dbacp05882 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | MBD-MB-435s | Prostate cancer | IC50 : 15.44 µM |
| dbacp05886 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | PC-3 | Prostate cancer | IC50 : 5.79 µM |
| dbacp05890 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | U251-MG | Prostate cancer | IC50 : 16.14 µM |
| dbacp05894 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | MCF-7) | Prostate cancer | IC50 : 20.19 µM |
| dbacp05898 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | HMEC-1 | Prostate cancer | IC50 : 79.50 µM |
| dbacp05941 | Retro | LGGIVSAVKKIVDFLG | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Prostate tumor cell line | Prostate cancer | IC50 : >10 µM |
| dbacp05965 | RGD-tachyplesin | CRGDCGGKWCFRVCYRGICYRRCR | Not found | Inducing apoptosis | Not specified | TSU | Prostate cancer | Not found |
| dbacp05966 | RGD-tachyplesin | CRGDCGGKWCFRVCYRGICYRRCR | Not found | Inducing apoptosis | Not specified | B16 | Prostate cancer | Not found |
| dbacp05967 | RGD-tachyplesin | CRGDCGGKWCFRVCYRGICYRRCR | Not found | Inducing apoptosis | Not specified | Cos-7 | Prostate cancer | Not found |
| dbacp05968 | RGD-tachyplesin | CRGDCGGKWCFRVCYRGICYRRCR | Not found | Inducing apoptosis | Not specified | NIH-3T3 | Prostate cancer | Not found |
| dbacp05985 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | H157 | Prostate cancer | IC50 : 58.18 µM |
| dbacp05989 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | MBD-MB-435s | Prostate cancer | IC50 : 179.00 µM |
| dbacp05993 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | PC-3 | Prostate cancer | IC50 : 792.60 µM |
| dbacp05997 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | U251-MG | Prostate cancer | IC50 : 278.30 µM |
| dbacp06001 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | MCF-7 | Prostate cancer | IC50 : 316.90 µM |
| dbacp06005 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | HMEC-1 | Prostate cancer | IC50 : 1185.00 µM |
| dbacp06027 | SCH-P10 | DYVP | Marine invertebrates | Inducing apoptosis | MTT assay | DU-145 | Prostate cancer | IC50 : 1.21 mg/mL |
| dbacp06028 | SCH-P10 | DYVP | Marine invertebrates | Inducing apoptosis | MTT assay | PC-3 | Prostate cancer | IC50 : 1.09 mg/mL |
| dbacp06029 | SCH-P9 | LPGP | Marine invertebrates | Inducing apoptosis | MTT assay | DU-145 | Prostate cancer | IC50 : 1.21 mg/mL |
| dbacp06030 | SCH-P9 | LPGP | Marine invertebrates | Inducing apoptosis | MTT assay | PC-3 | Prostate cancer | IC50 : 1.09 mg/mL |
| dbacp06058 | Sepia ink oligopeptide (SIO) | QPK | Not found | Inducing apoptosis | CCK-8 assay | DU-145 | Prostate cancer | IC50 : < 5 mg/mL |
| dbacp06059 | Sepia ink oligopeptide (SIO) | QPK | Not found | Inducing apoptosis | CCK-8 assay | PC-3 | Prostate cancer | IC50 : < 5 mg/mL |
| dbacp06060 | Sepia ink oligopeptide (SIO) | QPK | Not found | Inducing apoptosis | CCK-8 assay | LNCaP | Prostate cancer | IC50 : < 10 mg/mL |
| dbacp06294 | Tetramer of peptide-paclitaxel conjugate | (K-Aib-C(CH2CO-2'-Pac))4 | Synthetic peptide paclitaxel conjugate | Not specified | MTT/MTS assay | DU | Prostate cancer | IC50 : 1.30 nM |
| dbacp06339 | Transferrin receptor (TfR)-lytic hybrid peptide | THRPPMWSPVWPGGGKLlLKlLkkLLKlLKKK | Transferrin receptor (TfR) | Disintegration of cell membrane | WST-1 assay | LNCaP | Prostate cancer | IC50 : 6.2 µM |
| dbacp06347 | Trimer of peptide-paclitaxel conjugate | (K-Aib-C(CH2CO-2'-Pac))3 | Synthetic peptide paclitaxel conjugate | Not specified | MTT/MTS assay | DU | Prostate cancer | IC50 : 3.88 nM |
| dbacp06352 | Tropomyosin alpha-1 chain | MDAIKKKMQMLKLDKENALDRAEQAEADKKAAEERSKQLEDELVALQKKLKGTEDELDKYSESLKDAQEKLELADKKATDAESEVASLNRRIQLVEEELDRAQERLATALQKLEEAEKAADESERGMKVIENRAQKDEEKMEIQEIQLKEAKHIAEEADRKYEEVARKLVIIEGDLERAEERAELSESKCAELEEELKTVTNNLKSLEAQAEKYSQKEDKYEEEIKVLTDKLKEAETRAEFAERSVTKLEKSIDDLEDELYAQKLKYKAISEELDHALNDMTSI | Chicken | Not specified | Endothelial Cell Binding assay | HUVEC | Prostate cancer | IC50 : 155 ± 49 μM |
| dbacp06363 | TsAP-2 | FLGMIPGLIGGLISAFK | Venom-derived cDNAlibrary of the Brazilian yellow scorpion | Not specified | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 13.3 µM |
| dbacp06371 | TsAP-S1 | FLSLIPKLVKKIIKAFK | Derivative of TsAP-1, Brazilian yellow scorpion venom peptide | Not specified | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 2.1 µM |
| dbacp06379 | TsAP-S2 | FLGMIPKLIKKLIKAFK | Derivative of TsAP-1, Brazilian yellow scorpion venom peptide | Not specified | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 1.6 µM |
| dbacp06566 | Z24 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | PC-3 | Prostate cancer | Not found |
| dbacp06582 | Z44 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients;Induce osmotic lysis; Membrane damage | Trypan blue assay | PC-3 | Prostate cancer | Not found |
| dbacp06613 | Maculatin 1.3 | GLLGLLGSVVSHVVPAIVGHF | Fringed Tree Frog, Australia | Disruption of either cancer or bacterial cell membrane integrity | Not specified | Not specified | Prostate cancer | IC50 : 10−5 to 10−6 M |
| dbacp06617 | LA3IK | LAIAVK | Migration and invasion enhancer 1 (MIEN1) | Targeting the MIEN1 signaling pathway | MTT assay | PC-3 | Prostate Cancer | IC50 = 321.4 ± 11.79 µM |
| dbacp06618 | LA3IK | LAIAVK | Migration and invasion enhancer 1 (MIEN1) | Targeting the MIEN1 signaling pathway | MTT assay | DU-145 | Prostate Cancer | IC50 = 335.7 ± 3.09 µM |
| dbacp06621 | D-LA3IK | laiavk | Migration and invasion enhancer 1 (MIEN1) | Targeting the MIEN1 signaling pathway | MTT assay | PC-3 | Prostate Cancer | IC50 = 98.71 ± 6.17 µM |
| dbacp06622 | D-LA3IK | laiavk | Migration and invasion enhancer 1 (MIEN1) | Targeting the MIEN1 signaling pathway | MTT assay | DU-145 | Prostate Cancer | IC50 = 89.11 ± 8.12 µM |
| dbacp06625 | LA3IK-SCR | LAKAVI | Migration and invasion enhancer 1 (MIEN1) | Targeting the MIEN1 signaling pathway | MTT assay | PC-3 | Prostate Cancer | IC50 = 319 ± 13.64 µM |
| dbacp06626 | LA3IK-SCR | LAKAVI | Migration and invasion enhancer 1 (MIEN1) | Targeting the MIEN1 signaling pathway | MTT assay | DU-145 | Prostate Cancer | IC50 = 351.76 ± 7.18 µM |
| dbacp06629 | RP-7 | RPPCVIL | Migration and invasion enhancer 1 (MIEN1) | Targeting the MIEN1 signaling pathway | MTT assay | PC-3 | Prostate Cancer | IC50 = 113 ± 8.02 µM |
| dbacp06630 | RP-7 | RPPCVIL | Migration and invasion enhancer 1 (MIEN1) | Targeting the MIEN1 signaling pathway | MTT assay | DU-145 | Prostate Cancer | IC50 = 120.72 ± 7.08 µM |
| dbacp06633 | D-RP-7 | rppcvil | Migration and invasion enhancer 1 (MIEN1) | Targeting the MIEN1 signaling pathway | MTT assay | PC-3 | Prostate Cancer | IC50 = 101 ± 5.73 µM |
| dbacp06634 | D-RP-7 | rppcvil | Migration and invasion enhancer 1 (MIEN1) | Targeting the MIEN1 signaling pathway | MTT assay | DU-145 | Prostate Cancer | IC50 = 121.59 ± 6.56 µM |
| dbacp06637 | RP7 SCR | RPPLVIC | Migration and invasion enhancer 1 (MIEN1) | Targeting the MIEN1 signaling pathway | MTT assay | PC-3 | Prostate Cancer | IC50 = 128 ± 11.65 µM |
| dbacp06638 | RP7 SCR | RPPLVIC | Migration and invasion enhancer 1 (MIEN1) | Targeting the MIEN1 signaling pathway | MTT assay | DU-145 | Prostate Cancer | IC50 = 137 ± 5.98 µM |
| dbacp06670 | Crabrolin | FLPLILRKIVTAL | European hornet (Vespa crabro) | Not available | MTT assay | PC-3 | Prostate Cancer | IC50 = 32.13 μM |
| dbacp06675 | Crabrolin-4R | FLPRILRKIVTAL | Synthetic Analog of Crabrolin | Not available | MTT assay | PC-3 | Prostate Cancer | IC50 = 17.98 μM |
| dbacp06680 | Crabrolin-4K | FLPKILRKIVTAL | Synthetic Analog of Crabrolin | Not available | MTT assay | PC-3 | Prostate Cancer | IC50 = 20.58 μM |
| dbacp06685 | Crabrolin-TR | FLPRILRKIVRAL | Synthetic Analog of Crabrolin | Not available | MTT assay | PC-3 | Prostate Cancer | IC50 = 3.944 μM |
| dbacp06690 | Crabrolin-FR | RLPRILRKIVRAL | Synthetic Analog of Crabrolin | Not available | MTT assay | PC-3 | Prostate Cancer | IC50 = 15.87 μM |
| dbacp06695 | Crabrolin-AR | RLPRILRKIVRRL | Synthetic Analog of Crabrolin | Not available | MTT assay | PC-3 | Prostate Cancer | IC50 = 28.78 μM |
| dbacp06700 | Crabrolin-PR | RLRRILRKIVRRL | Synthetic Analog of Crabrolin | Not available | MTT assay | PC-3 | Prostate Cancer | IC50 = 22.37 μM |
| dbacp07009 | ST101 | vaeareelerlearlgqargelkkwkmrrnqfwlklqr | Synthetic | Prevents C/EBPβ dimerization, induces degradation | Annexin V/ PI staining assay | DU-145 | Prostate Cancer | mean EC50 value of 2.1 ± 0.4 μmol/L |
| dbacp07028 | [G10a]-SHa | FLSGIVGMLaKLF | Analog of temporin SHa | Dendrimerization enhances stability, selectivity, anticancer efficacy | Resazurin dye assay | PC-3 | Prostate Cancer | IC50 = 13.04 ± 1.99 µM |
| dbacp07035 | [G10a]2-SHa | FLSGIVGMLaKLFKFLKaLMFLSGIVG | Analog of temporin SHa | Dendrimerization enhances stability, selectivity, anticancer efficacy | Resazurin dye assay | PC-3 | Prostate Cancer | IC50 = 6.31 ± 0.66 µM |
| dbacp07042 | [G10a]3-SHa | FLSGIVGMLaKLFFLSGIVGMLaKLFFLSGIVGMLaKLFKK | Analog of temporin SHa | Dendrimerization enhances stability, selectivity, anticancer efficacy | Resazurin dye assay | PC-3 | Prostate Cancer | IC50 = 1.84 ± 0.17 µM |
| dbacp07048 | Jeff-[G10a]2-SHa | FLSGIVGMLaKLF-jeff-FLSGIVGMLaKLF | Analog of temporin SHa | Dendrimerization enhances stability, selectivity, anticancer efficacy | Resazurin dye assay | PC-3 | Prostate Cancer | IC50 = 57.99 ± 5.04 µM |
| dbacp07051 | Temporin-PKE | FLPLIIGALSSLLPKIF | skin secretion of Pelophylax kl. esculentus | Charge-optimized membranolysis induces apoptosis. | MTT assay | PC-3 | Prostate Cancer | IC50 = 7.29 μM |
| dbacp07056 | Temporin-PKE-2K | FLPLIIGKLSSLLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | PC-3 | Prostate Cancer | IC50 = 2.64 μM |
| dbacp07061 | Temporin-PKE-K12 | FLPLIIGALSSKLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | PC-3 | Prostate Cancer | IC50 = 27.32 μM |
| dbacp07066 | Temporin-PKE-3K | FLPKIIGKLSSLLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | PC-3 | Prostate Cancer | IC50 = 3.01 μM |
| dbacp07071 | Temporin-PKE-4K | FLPKIIGKLSSKLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | PC-3 | Prostate Cancer | IC50 = 49.50 μM |
| dbacp07076 | Temporin-PKE-i | FLPLIIGALSSLLPKiF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | PC-3 | Prostate Cancer | IC50 = 3.35 μM |
| dbacp07081 | Temporin-PKE-3i | FLPLiiGALSSLLPKiF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | PC-3 | Prostate Cancer | IC50 = 167 μM |
| dbacp07105 | rScyreprocin | MKEDSNILDKTAKMTKQNKALLFTAGGAAAFMAGYYYYHCNYRNPAPKKSGSTTSQDKTDAQAVQSIPSPSGNKGKESKDPKVKHHHHHH | Recombinant product of Scyreprocin | Membrane disruption triggers ROS-mediated apoptosis | MTS assay | DU-145 | Prostate cancer | IC50 = 1158.30 µM |
| dbacp07108 | Nigrocin-M1 | GLLGKILGAGKKVLLGVSGLL | Synthetic | Membrane disruption mediates selective cytotoxicity. | MTT assay | PC-3 | Prostate cancer | IC50 = 31.27 μM |
| dbacp07259 | t-DPH1-K4 | GLWKKIKNVAAAAGKAALGAL | Analogue of t-DPH1 | Membrane disruption induces apoptotic signaling. | MTT assay | PC-3 | Prostate Cancer | IC50 = 18.99 μM |
| dbacp07263 | t-DPH1-5K | GLWKKIKNVAKAAGKAALGAL | Analogue of t-DPH1 | Membrane disruption induces apoptotic signaling. | MTT assay | PC-3 | Prostate Cancer | IC50 = 2.605 μM |
| dbacp07267 | t-DPH1-6K | GLWKKIKNVAKAAGKAAKGAL | Analogue of t-DPH1 | Membrane disruption induces apoptotic signaling. | MTT assay | PC-3 | Prostate Cancer | IC50 = 55.65 μM |
| dbacp07271 | t-DPH1-6KW | WLWKKIKNVAKAAGKAAKGAL | Analogue of t-DPH1 | Membrane disruption induces apoptotic signaling. | MTT assay | PC-3 | Prostate Cancer | IC50 = 118.4 μM |
| dbacp07313 | B1OS-L | FLPLIASLAGNVVPKIFCKITKRC | B-1OS | Not Available | MTT assay | PC-3 | Prostate Cancer | IC50 = 5.473 µM |
| dbacp07318 | B1OS-D-L | FlPLIASLAGNVVPKIFCKITKRC | B-1OS | Not Available | MTT assay | PC-3 | Prostate Cancer | IC50 = 2.629 µM |
| dbacp07398 | Pugnin A | RLMRIFRILKLAR | Synthetic | Membrane disruption induces necrotic death | MTT assay | PC-3 | Prostate Cancer | 74% Cytotoxicity at 100 µM |
| dbacp07400 | Pugnin B | RMMRIFWVIKLAR | Synthetic | Membrane disruption induces necrotic death | MTT assay | PC-3 | Prostate Cancer | 90% Cytotoxicity at 100 µM |
| dbacp07410 | Dermaseptin-TO | ALWKDLLKNVGIAAGKAALNKVTDMVNQ | Phyllomedusa tomopterna | Membrane disruption induces cell death | MTT assay | PC-3 | Prostate Cancer | Graph Figure-7 |
| dbacp07437 | A4K14 - Citropin 1.1 - Sp 7 | GLFAVR8KKVASVS5KGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | C4-2B | Prostate Cancer | IC50 = 10.23 µM |
| dbacp07441 | A4K14 - Citropin 1.1 - Sp 6 | GR8FAVIKKS5ASVIKGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | C4-2B | Prostate Cancer | IC50 = 35.84 µM |
| dbacp07445 | A4K14 - Citropin 1.1 - Sp 5 | GLFAVIKKVAS5VIKS5L | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | C4-2B | Prostate Cancer | IC50 = 11.9 µM |
| dbacp07449 | A4K14 - Citropin 1.1 - Sp 4 | GLFAVIKKS5ASVS5KGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | C4-2B | Prostate Cancer | IC50 = 8.9 µM |
| dbacp07453 | A4K14 - Citropin 1.1 - Sp 3 | GLFAVS5KKVS5SVIKGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | C4-2B | Prostate Cancer | IC50 = 17.89 µM |
| dbacp07457 | A4K14 - Citropin 1.1 - Sp 2 | GLFAS5IKKS5ASVIKGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | C4-2B | Prostate Cancer | IC50 = 10.14 µM |
| dbacp07461 | A4K14 - Citropin 1.1 - Sp 1 | GS5FAVS5KKVASVIKGL | Synthetic | Stapled peptide enhances helical apoptosis | CCK-8 assay | C4-2B | Prostate Cancer | IC50 = 8.94 µM |
| dbacp07480 | (LLKK)4 linear peptide | LLKKLLKKLLKKLLKK | Synthetic | Apoptosis, drug-resistance reversal, tumor suppression | MTT assay | PC-3 | Prostate Cancer | Cell Viability (%) ~ 17.1 ± 5.0 at 30 µg/mL |
| dbacp07484 | 2-arm branched peptide | [LLKKLLKK]2kC | Synthetic | Apoptosis, drug-resistance reversal, tumor suppression | MTT assay | PC-3 | Prostate Cancer | Cell Viability (%) ~ 73.5 ± 2.2 at 30 µg/mL |
| dbacp07488 | 4-arm branched peptide | {[LLKKLLKK]2kC}2 | Synthetic | Apoptosis, drug-resistance reversal, tumor suppression | MTT assay | PC-3 | Prostate Cancer | Cell Viability (%) ~ 49.0 ± 0.8 at 30 µg/mL |
| dbacp07501 | Brevinin-1Ha | FALGAVTCLIRTKCKVLPKLF | Analogue of Brevinin-1H | α-helix enhances antimicrobial, anticancer activity | MTT assay | PC-3 | Prostate Cancer | IC50 = 186.9 µM |
| dbacp07505 | Brevinin-1HY | FALGAVTKVLYKLFCLITRKC | Analogue of Brevinin-1H | α-helix enhances antimicrobial, anticancer activity | MTT assay | PC-3 | Prostate Cancer | IC50 = 5.425 µM |
| dbacp07514 | Dermaseptin-PP | ALWKDMLKGIGKLAGKAALGAVKTLV | Phyllomedusa palliata | Membrane disruption triggers dual apoptosis | MTT assay | PC-3 | Prostate Cancer | IC50 = 4.15 μM |
| dbacp07852 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Phyllomedusa tarsius | Membrane disruption and cationic enhancement | MTT assay | PC-3 | Prostate Cancer | IC50 = 21.78 µM |
| dbacp07857 | K8, 23-DPT9 | GLWSKIKKAAKTAGKAALGFVNKMV | Synthetic | Membrane disruption and cationic enhancement | MTT assay | PC-3 | Prostate Cancer | IC50 = 9.97 µM |
| dbacp07863 | HN-1 | FALGAVTKLLPSLLCMITRKC | Amolops hainanensis | Apoptosis induction and immune activation | MTT assay | PC-3 | Prostate Cancer | Not Available |
| dbacp07870 | R-Lycosin I derivative 8a | RGWFRAMRSIARFIARERLRGHL | Monosaccharide Analogue of Anticancer Peptide R-Lycosin-I | GLUT1-mediated uptake enhances cytotoxicity | CCK-8 assay | PC-3 | Prostate Cancer | IC50 = 6.9 ± 0.4 µM |
| dbacp07876 | R-Lycosin I derivative 8b | RGWFRAMRSIARFIARERLRGHL | Monosaccharide Analogue of Anticancer Peptide R-Lycosin-I | GLUT1-mediated uptake enhances cytotoxicity | CCK-8 assay | PC-3 | Prostate Cancer | IC50 = 4.9 ± 0.2 µM |
| dbacp07938 | Pantinin-1 | GILGKLWEGFKSIV | Synthetic | Selective binding, membrane disruption, apoptosis | MTS assay | DU-145 | Prostate Cancer | IC50 = 47.5 ± 2.0 µM |
| dbacp07940 | Pantinin-2 | IFGAIWKGISSLL | Synthetic | Selective binding, membrane disruption, apoptosis | MTS assay | DU-145 | Prostate Cancer | IC50 = 16.5 ± 1.0 µM |
| dbacp07942 | Pantinin-3 | FLSTIWNGIKSLL | Synthetic | Selective binding, membrane disruption, apoptosis | MTS assay | DU-145 | Prostate Cancer | IC50 = 17.3 ± 1.0 µM |
| dbacp07951 | S-24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Synthetic Analogue of Ranatuerin-2PLx | R2PLx induces caspase-dependent apoptosis | MTT assay | PC-3 | Prostate Cancer | IC50 = 792.60 µM |
| dbacp07957 | DP-2 | GRKKRRQRRRGALWKSLLKNVGKA | Synthetic | DRS-DU-1 induces selective tumor cytotoxicity | MTT assay | PC-3 | Prostate Cancer | IC50 = 6.75 μM |
| dbacp07990 | K5, 17-DPS3 | ALWKKILKNAGKAALNKINQIVQ | Analogue of Dermaseptin-PS3 | Enhanced cationicity/hydrophobicity increases cytotoxicity | MTT assay | PC-3 | Prostate Cancer | IC50 = 18.20 μM |
| dbacp07992 | L10, 11-DPS3 | ALWKDILKNLLKAALNEINQIVQ | Analogue of Dermaseptin-PS3 | Enhanced cationicity/hydrophobicity increases cytotoxicity | MTT assay | PC-3 | Prostate Cancer | IC50 = 1.85 μM |
| dbacp08057 | TAK-448 | ywNTF(AzGly)R(Me)W | Synthetic | TAK-448 reduces testosterone, inhibits tumor | Given i.h. | VCaP | Prostate Cancer | Had greater anti-tumor effects in VCaP xenograft model |
| dbacp08066 | Temporin-PE | FLPIVAKLLSGLL | Pelophylax kl. esculentus | Modulates membrane interactions | MTT assay | PC-3 | Prostate Cancer | IC50 = 38.56 μM |
| dbacp08070 | temporin-PEa | FLYIVAKLLSGLL | Synthetic analog of Temporin-PE | Modulates membrane interactions | MTT assay | PC-3 | Prostate Cancer | IC50 = 27.62 μM |
| dbacp08074 | temporin-PEb | FLPIVAKLLSGLLGRKKRRQRRR | Synthetic analog of Temporin-PE | Modulates membrane interactions | MTT assay | PC-3 | Prostate Cancer | IC50 = 3.051 μM |
| dbacp08079 | APETx4 | GTTCYCGKTIGIYWFGKYSCPTNRGYTGSCPYFLGICCYPVD | Anthopleura elegantissima | Not Available | CellTox Green Dye assay | LNCaP | Prostate Cancer | Green object count = 300 /mm2 at 20 μM |
| dbacp08153 | IL-1 | FKAGGFIKKLWRSLLA | Synthetic | Ile/Leu residues crucially mediate cytolysis | MTT assay | PC-3 | Prostate Cancer | IC50 = 58.4 ± 13.7 μM |
| dbacp08156 | IL-2 | FKIGGFAKKLWRSLLA | Synthetic | Ile/Leu residues crucially mediate cytolysis | MTT assay | PC-3 | Prostate Cancer | IC50 = 43.6 ± 7.9 μM |
| dbacp08159 | IL-3 | FKIGGFIKKAWRSLLA | Synthetic | Ile/Leu residues crucially mediate cytolysis | MTT assay | PC-3 | Prostate Cancer | IC50 = 74.9 ± 13.3 μM |
| dbacp08162 | IL-4 | FKIGGFIKKLWRSALA | Synthetic | Ile/Leu residues crucially mediate cytolysis | MTT assay | PC-3 | Prostate Cancer | IC50 = 35.5 ± 3.9 μM |
| dbacp08165 | IL-5 | FKIGGFIKKLWRSLAA | Synthetic | Ile/Leu residues crucially mediate cytolysis | MTT assay | PC-3 | Prostate Cancer | IC50 = 22.0 ± 2.6 μM |
| dbacp08177 | Peptide - 1 | GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK | Synthetic | Not Available | CellTiter-Glo assay | PC-3 | Prostate Cancer | Not Available |
| dbacp08270 | ZXR-2 | FKIGGFIKKLWRSLLA | Synthetic | Not Available | MTT assay | PC-3 | Prostate Cancer | IC50 = 14.2 ± 0.5 μM |
| dbacp08318 | Sample Peptide 2 from US011339203B2 | FIGNLALSDLLAGVAYTANLLLKKRTLRKNDRKKR | Synthetic | Not Available | CCK-8 assay | PC-3 | Prostate Cancer | Cell Viability = 2.5% at 25 μM |